United BioPharma, Inc.

NEW YORK, Nov. 9, 2023 /PRNewswire/ -- The Anti-CD20 monoclonal antibodies (maABs) market is expected to grow by USD 11.42 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 10.31% during the forecast period, according to Technavio Research. The market has been segmented by product (oncology, neurology, and immunology), type (first generation anti-CD20 monoclonal antibody, second generation anti-CD20 monoclonal antibody, and third generation anti-CD20 monoclonal antibody), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 57% to the growth of the global market during the forecast period. The growth of the market in North America is due to the high incidence and prevalence of hematological malignancies such as non-Hodgkin lymphoma (NHL). This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global Anti-CD20 Monoclonal Antibodies (mABs) Market 2024-2028 Company Profile: Acrotech Biopharma Inc., Amgen Inc., AstraZeneca Plc, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd. Amgen Inc. - The company offers anti-CD20 monoclonal antibodies such as Bax active monomer recombinant antibody 6A7 OAAV00544 and CD52 recombinant antibody campath 1H OAAV00552. To gain access to more company profiles available with Technavio, buy the report! Anti-CD20 Monoclonal Antibodies (mABs) Market: Segmentation Analysis The market share growth by the oncology segment will be significant during the forecast period. It is the availability of anti-CD20 mAbs in common cancer indications that has driven this segment's growth. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report "Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio Anti-CD20 Monoclonal Antibodies (mABs) Market: Market Dynamics Increased use of combination therapies High target affinity and specificity of anti-CD20 mABs Strong pipeline and recent approvals Key Driver Increased use of combination therapies is a key factor driving market growth. In cases where the effectiveness and poor tolerability of monotherapy products are worse than in combination therapy, a combination treatment is usually preferable. In combination with other medicines to treat comorbid diseases, the market has seen a strong increase in the use of mABs against CD20. Major Trend The development of CD20 bispecific antibodies is the primary trend shaping market growth. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information. Related Reports: The breast cancer monoclonal antibodies market size is estimated to grow by USD 15 billion at a CAGR of 12.5% between 2022 and 2027. The Biosimilars Market size is estimated to grow by USD 42.23 billion between 2022 and 2027, accelerating at a CAGR of 23% during the forecast period. What are the key data covered in this anti-CD20 monoclonal antibodies (mABs) market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the anti-CD20 monoclonal antibodies (mABs) market between 2023 and 2028. Precise estimation of the anti-CD20 monoclonal antibodies (mABs) market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the anti-CD20 monoclonal antibodies (mABs) market across North America, Europe, Asia, and ROW A thorough analysis of the market's competitive landscape and detailed information about companies Comprehensive analysis of factors that will challenge the growth of the anti-CD20 monoclonal antibodies (mABs) market companies. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Product Market Segmentation by Type Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

中国台湾生物技术公司正蓬勃发展。多年来，中国台湾方面采取积极主动的姿态，通过监管和促进政策，推进和引导生物科技产业。自1980年代以来，当地政府一直在投资该行业，并于1984年成立了旨在推动中国台湾生物技术和制药业的非营利组织生物技术发展中心。在政策扶持等各方润土下，中国台湾创新生物科技公司逐步在世界赢得一席之地。知名外媒Labiotech统计了中国台湾10家创新生物科技公司，领域分别聚焦于植物药、单克隆抗体(mAb)药物、癌症细胞免疫疗法、人用疫苗、小分子药物等。总的来看，这些Biotech成立时间跨度较大，但大多集中于2000年前后。其中，历史最为悠久的是成立于1965年的老牌企业Adimmune，发展至今已有50多年历史，专注于人用疫苗的研发、加工、制造和销售。而最年轻的Biotech至今也已发展5年，为2017年成立的Acepodia。在这10家企业中，总部一半坐落在台北。在2021年，中国台湾生物科技公司营收也创下新高，创造了超过7000亿新台币（233.7亿美元）的收入，比2020年增长了近10%。以下是中国台湾涉及应用生物技术和制药领域的10家生物技术公司（排名不分先后）：1.TailMed Biologics地点：台北成立时间：2007TailMed Biologics是单克隆抗体(mAb)药物的开发商和制造商，并提供CDMO服务。该公司由著名的艾滋病研究人员David Ho创立。2007年，基因泰克将用于治疗HIV/AIDS的单克隆抗体Trogarzo(ibalizumab)授权给TailMed，以完成该药物的开发。2018年和2019年，ibalizumab分别获得美国食品药品监督管理局（FDA）和欧洲药品管理局的批准。TailMed目前正在研究ibalizumab的其他给药途径，这些新技术可以克服ibalizumab耐药性和广泛中和HIV-1抗体。2. PhytoHealth Corp.地点：台北成立时间：1998PhytoHealth是第一家在中国台湾股票市场上市的药物开发公司。该公司专注于开发植物药——以中药为基础的草药化合物。2010年，中国台湾批准了PhytoHealth的抗癌疲劳植物药，这是一种从开花植物黄芪中分离出来的冷冻干燥碳水化合物分子的注射剂。该药物已被美国FDA授予用于特发性血小板减少性紫癜的孤儿药指定——一种血液中血小板数量异常低的血液疾病。此外，PhytoHealth还有其它几款正在开发的候选药物，其中三个已经完成了3期临床试验，并已获得美国FDA快速通道指定。3.Lumosa Therapeutics地点：台北成立时间：2000Lumosa Therapeutics是一家临床阶段的公司，为神经和肿瘤疾病开发解决方案。该公司首个上市产品Naldebain是世界上第一个用于术后疼痛的镇痛剂注射剂，可提供长达7天的持续镇痛作用，同时绕过与阿片类药物相关的物质依赖。其产品管线中的另一种产品为由合成肽和抗氧化剂组成的新型分子，它可以恢复阻塞的血流而不会导致出血，用于治疗急性缺血性中风，这是一项未得到满足的医疗需求，因为由于出血风险增加，美国FDA批准的唯一一种缺血性卒中治疗仅限于卒中发病3-4.5小时内的患者，使得该药物在临床上的实际使用率仅为1-8%。4. AltruBio地点：台北成立时间：2001AltruBio正开发一种免疫调节剂，用于治疗和预防炎症和自身免疫性疾病。该公司最先进的项目neihulizumab是一种一流的抗体，具有独特的作用机制：它选择性地靶向并消耗参与免疫介导疾病的慢性活化T细胞，保持其他T细胞完整以维持宿主防御。Neihulizumab在银屑病关节炎和溃疡性结肠炎的2a期试验中显示出临床疗效，目前正处于急性移植物抗宿主病的1期试验中。另一种T细胞调节剂正处于临床前开发阶段，可作为实体器官移植后长期给予免疫抑制药物的替代方案。5.ScinoPharm Taiwan地点：台南成立时间：1997ScinoPharm是一家全球性的活性药物成分(API)制造商，从事其研究、开发、制造和销售。除了作为全球制药行业的主要原料药供应商外，该公司还提供外包服务，供应的主要产品包括抗癌原料药、蛋白质药物、多肽、新型小分子药物和注射剂。6. Acepodia地点：新北市成立时间：2017Acepodia专注于使用其专有的抗体细胞偶联（ACC）平台开发下一代癌症细胞免疫疗法。ACC是一种肿瘤靶向技术，可简单且经济有效地将抗体直接连接到γ-δ(γδ)T细胞和自然杀伤(NK)细胞，以增强其肿瘤杀伤能力，而无需进行基因操作。该公司管道中最先进的产品是一种现成的ACC-oNK细胞疗法，与HER2抗体结合，用于治疗表达HER2的肿瘤，目前处于第一阶段测试中。7. Caliway Biopharmaceuticals地点：新北市成立时间：2012Caliway Biopharmaceuticals主要开发用于治疗和美容目的的新型小分子药物。旗下重要候选产品是一款可以破坏注射部位脂肪细胞的注射剂，该药物已经完成了非手术减脂的2a期测试，预计其适应症将扩展到Dercum病和脂肪瘤（这两种疾病都是脂肪组织块在皮肤下生长的疾病）。临床开发中的其他产品主要针对骨关节炎、糖尿病以及皮肤色素沉着过度和衰老。8. Adimmune Corp.地点：台中成立时间：1965Adimmune是本次中国台湾生物技术公司名单中历史最悠久的公司，专注于人用疫苗的研发、加工、制造和销售。它是亚洲唯一一家同时拥有欧盟良好生产规范和美国FDA认证的流感疫苗制造商。除了在国内供应超过3000万剂流感疫苗外，Adimmune还向国际市场扩张：其针对四种不同抗原的四价流感疫苗在赛诺菲的帮助下于美国实现商业化，并在美国完成了3期试验。其他产品包括破伤风、日本脑炎疫苗以及针对肠道病毒71的疫苗等。Adimmune还在开发用于大规模生产DNA的质粒生产平台，以满足对DNA和RNA疗法不断增长的需求。9. Steminent Biotherapeutics地点：台北成立时间：2009Steminent是一家干细胞研发公司，在其Stemchymal产品组合下开发新型细胞疗法。Stemchymal产品由从人类供体来源的脂肪组织中分离出来的干细胞制成。Steminent最先进的细胞疗法正处于治疗脊髓小脑性共济失调的第二阶段测试中——这是一种罕见的神经退行性疾病，会导致协调性进行性困难。除了急性肝功能衰竭和药物性肝损伤的临床前阶段项目外，其他疗法还包括治疗1期膝关节骨性关节炎的候选药物。10. United BioPharma地点：新竹成立时间：2013United BioPharma专注于开发用于治疗传染病、免疫疾病和癌症的创新单克隆抗体。旗下主要候选药物是一种单克隆抗体，正在研究用于2期和3期试验中三种不同的HIV适应症。其余正在进行临床试验的候选药物包括用于治疗复发性生殖器疱疹和慢性自发性荨麻疹的单克隆抗体。该公司还拥有三种用于乳腺癌、胃癌和慢性淋巴细胞白血病临床前开发的单克隆抗体。参考来源：《10 biotech companies to know in Taiwan》https://www.labiotech.eu/best-biotech/10-biotech-companies-taiwan/登记邮箱信息订阅E药经理人信息服务扫描二维码精彩推荐集采 | 国谈 | 医保动态 | 药审 | 人才 | 薪资 | 榜单 | CAR-T | PD-1 | mRNA | 单抗 | 商业化 | 国际化启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 医药界·E药经理人 | 中国医药手册创新100强榜单 | 恒瑞 | 中国生物制药 | 百济 | 石药 | 信达 | 君实 | 复宏汉霖 ｜翰森 | 康方生物 | 上海医药 | 和黄医药 | 东阳光药 |  荣昌 | 亚盛医药 | 齐鲁制药 | 康宁杰瑞 | 贝达药业 | 微芯生物 | 复星医药 ｜再鼎医药跨国药企50强榜单 | 辉瑞 | 艾伯维 | 诺华 | 强生 | 罗氏 | BMS | 默克 | 赛诺菲 | AZ | GSK | 武田 | 吉利德科学 | 礼来 | 安进 | 诺和诺德 | 拜耳 | 莫德纳 | BI | 晖致 | 再生元

TAIPEI, Aug. 31, 2022 /PRNewswire/ -- United BioPharma (UBP) announced today that the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of this study is to assess the safety and antiviral activity of UB-421 in combination with optimized background ART in HIV-1 infected patients with multi-drug resistance (MDR). The study protocol is entitled: "A Single arm Open Label Phase 2 trial of anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with Multi-Drug Resistant HIV-1 Infection." In this trial sponsored by the NIAID/NIH, UBP will be responsible for supplying the investigational drug, UB-421. UBP has been collaborating with NIAID since 2015 to study the unique characteristic properties of UB-421 for treatment of HIV. The potent efficacy of UB-421 against HIV clinical isolates resistant to HIV broadly neutralizing antibodies, entry inhibitors, and other antiretroviral drugs is well documented. "We are excited for the NIAID to recognize the effectiveness of UB-421 through extensive collaborative studies, and to sponsor a phase 2 clinical trial in multi-drug resistant HIV patients." said Dr. Shugene Lynn, the CEO and President of UBP. The treatment of HIV-1 infection with antiretroviral therapy (ART) has significantly decreased HIV-1-related mortality and transformed HIV-1 infection into a treatable chronic disease. Successive generations of ART agents have shown improved efficacy and tolerability while minimizing drug-related toxicities. However, the ability of HIV-1 to develop resistance to multiple classes of antiretroviral (ARV) drugs continues to present challenges to the treatment of some ARV treatment-experienced patients. Multi-drug resistant (MDR) HIV-1 has been associated with a higher risk of disease progression and death. Therefore, new agents and drug classes are necessary to keep up with ongoing viral mutations in an attempt to achieve sustained suppression of HIV-1 plasma viremia and prolong the life of persons with MDR HIV infection, as well as to prevent viral replication and transmission of such MDR strains. Drugs with novel mechanism of action, such as UB-421, are of particular interest because empirical resistance is unlikely. About UB-421 UB-421 is an Fc-aglycosylated, non-T cell depleting and CD4-specific humanized IgG1 derived from the parent murine B4, which binds to discontinuous, conformational epitopes on the HIV-receptor complex, including CD4 (domain 1), and competitively blocks HIV entry. Both the murine and humanized mAbs bind to CD4+ T cells with approximately 50-100-fold higher affinity than HIV-gp120. UB-421 has been shown to inhibit viral entry with remarkable viral load reduction potency in Phase 1 and Phase 2a clinical studies involving treatment-naïve HIV-infected patients. In the Phase 2 study with ART-stabilized HIV-infected patients, UB-421 monotherapy maintains viral suppression for up to 16 weeks without viral rebound in the absence of ART. UB-421 is currently in the stage of phase 2 and phase 3 clinical trials for ART substitution, treatment of multi-drug resistant HIV as well as proof-of-concept study of HIV functional cure. About United BioPharma United BioPharma (UBP) is a late clinical stage biopharmaceutical company that is dedicated to the development of novel monoclonal antibodies (mAbs) for infectious diseases, cancer and immune disorders. UBP is headquartered in Taiwan, with subsidiary companies in China, and liaison offices in the U.S. The company has a passionate global team, developing therapeutic mAbs and delivering affordable treatments to bring a better quality of life to patients. For more information, please visit the website at: SOURCE United BioPharma Inc.